STAT+: AbbVie smooths over a dispute about alleged theft of trade secrets for a new version of Botox

After two years of bickering, AbbVie (ABBV) and a marketing partner have settled a dispute in which they had accused two competitors of stealing trade secrets that were used to develop a rival product to the best-selling Botox treatment.

The settlement comes after the U.S. International Trade Commission in December decided that imports of the rival medicine, made by Evolus (EOLS) and Daewoong Pharmaceuticals, be halted for 21 months. The ruling was made in response to a complaint filed in 2019 by Allergan, which AbbVie has since acquired, and its partner Medytox.

Continue to STAT+ to read the full story…